-+ 0.00%
-+ 0.00%
-+ 0.00%

Bayer: In the phase III prostate cancer trial, darotamide combined with androgen deprivation therapy and radiation therapy reduced the risk of metastasis or death by 58%.

Zhitongcaijing·10/24/2026 06:33:01
Listen to the news
Bayer: In the phase III prostate cancer trial, darotamide combined with androgen deprivation therapy and radiation therapy reduced the risk of metastasis or death by 58%.